Dr. Derrick Katayama joined Legacy in July of 2015 as Principal Scientist. Previously Dr. Katayama held positions at Amylin, MedImmune, and Boehringer Ingelheim.
Dr. Joshua Stillahn joined Legacy as Scientist in 2016, after working in the integrated circuit industry. We are glad to have both John and Derrick working with us.
Dr. Ryan Holcomb was promoted to Principal Scientist, effective January 1, 2018.
According to ResearchGate, Dr. Manning had 1840 reads of his publications in 2015 and his work was cited 316 times in 2015 alone (over 7000 times overall). In addition, he has over 4000 reads on ResearchGate.
The review article, “Stability of Protein Pharmaceuticals: An Update”, published by Legacy scientists in 2010, has now been cited almost 300 times. It is recognized by Web of Science as a Highly Cited Article, of which only 1% are so designated.
As of July/August 2018, this highly cited paper (Manning et al., “Stability of Protein Pharmaceuticals : An Update, Pharm. Res, 2010, 27: 544-575) received enough citations to place it in the top 1% of the academic field of Pharmacology & Toxicology based on a highly cited threshold for the field and publication year.
The review article on buffers written by Legacy scientists (Zbacnik et al., J. Pharm. Sci. 2017, 106: 713-733) was listed as being of outstanding interest in a review article by Baek and Zydney, Current Opinion in Biotechnology 2018, 53: 59-64)
Ryan Manning heads Great Lakes Bio Design (Charlotte, MI), with a focus on AF4 method development and analysis of biopharmaceuticals. Great Lakes BioDesign (GLB) began operation in January of 2014. As part of our distributed analytical network, GLB has already contributed to more than a dozen different projects since its inception.
Ryan Manning will also present a poster on “AF4-MALLS Analysis of Surfactant Prorein-D” at the International Conference on Field-Flow Fractionation, to be held in South Carolina in April, 2018.